What is your preferred treatment for non-contiguous Stage IIA Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL)?

Topics: Radiation Oncology • Medical Oncology • Lymphoma • Hodgkin Lymphoma

NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario. What factors help your decision making?

Answer from: Medical Oncologist at Community Practice

Prognosis of patients with early stage NLP-HL is excellent with any treatment, and multi-institutional studies have shown 5-year survival rates of 98% (Michael S. et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020; 13...

Comments

Radiation Oncologist at New Hope Cancer Center
I have a 27-year-old female patient with NLPHL sta...

Medical Oncologist at Mayo Clinic College of Medicine and Science (Scottsdale)
Yes, I would use R-CHOP for a young patient with b...

Related Questions